Career Development Awards Provide Solid Foundation for Future Academic Pursuits
2012 Award Winners
Alan Ho, MD, PhD
“Targeting the Oncogenic Transcription Factor c-myb in Adenoid Cystic Carcinomas”
Geoffrey Oxnard, MD
“Characterizing a new familial lung cancer syndrome through the identification and study of patients with germline EGFR mutations”
Gopakumar Iyer, MD
“TSC-1: Mutational Analysis and Clinical Impact in Metastatic Bladder Cancer”
Kasiani Myers, MD
“Chemoprevention of Leukemia in a Genetically Susceptible Population”
Michaela Higgins, MD
“A Phase II trial of cabozantinib in women with metastatic hormone-receptor-positive breast cancer with involvement of bone”
Mrinal Gounder, MD
“A Phase III, double blind, randomized, placebo-controlled trial of sorafenib in desmoid tumors or aggressive fibromatosis (DT/DF)”
Paul Paik, MD
“Squamous Cell Carcinoma of the Lung Mutation Analysis Program (SQ-MAP)”
Philippe Bedard, MD, FRCPC
“A randomized, open-label phase II trial of combined pathway blockade for PI3K and MAPK pathway mutated breast, colorectal, non-small cell lung, and ovarian cancer”
Rom Leidner, MD
“Molecular Cytology in Barrett’s Esophagus”
Toni Zhong, MD
“The use of human acellular dermal matrix in one-stage implant breast reconstruction: A multicentered, randomized controlled trial”
William William, Jr., MD
“Non-coding RNAs as predictive biomarkers of benefit from epidermal growth factor receptor-targeted therapies in head and neck squamous cell carcinomas”
The Conquer Cancer Foundation of the American Society of Clinical Oncology is awarding 11 young investigators with Career Development Awards (CDAs) at this year’s Annual Meeting to establish themselves as independent clinical researchers.
The awards—totaling $2.1 million— will be presented during the Conquer Cancer Foundation Grants and Awards Ceremony in the Regency Ballroom at the Hyatt Regency McCormick Place this evening.
This year, all alumni of the grants program are also invited to the ceremony, which will be followed by a networking reception.
Since the award’s inception in 1992, the Foundation has awarded a total of more than $35 million in the form of the CDA, affecting the careers of 200 young oncologists. The CDA is a 3-year grant amounting to $200,000, distributed in allotments to the recipient’s institution; these funds are designed to alleviate costs associated with supporting the recipient’s research endeavors.
The CDA is offered to physicians who are in the first to third year of a fulltime, primary faculty appointment in a clinical department at an academic medical institution at the time of grant submission.
Applications are reviewed by the Conquer Cancer Foundation Grants Selection Committee using a peer-review process based on a variety of criteria.
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, received a 2003 CDA for research on sharing results with patients who had participated in clinical trials.
In a video interview featured on the Conquer Cancer Foundation website, she described the work of her and her colleagues as “a ground-breaking piece of research that we were able to accomplish.” They are now working on implementation of shared trial results routinely with patients both at their center and throughout the country.
“Without the support of the Conquer Cancer Foundation, that work would not have been able to have been accomplished as easily,” Dr. Partridge said. To view Dr. Partridge’s full interview, visit the “Who We Are” section of ConquerCancerFoundation.org and select “Researcher Spotlight.” Dr. Partridge was also a recipient of a 2001 Young Investigator Award and a 2010 Improving Cancer Care Grant, funded by Susan G. Komen for the Cure.
The 2012 CDAs were generously supported by the following: Amgen; The Breast Cancer Research Foundation; Genentech BioOncology; Lilly USA, LLC; Roche; and Sarcoma Foundation of America.
To donate to the Conquer Cancer Foundation’s Grants and Awards Program, visit the Donor Lounge, S401.